InMed Pharmaceuticals Inc. Logo

InMed Pharmaceuticals Inc.

Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.

INM | US

Overview

Corporate Details

ISIN(s):
CA4576375022
LEI:
Country:
United States of America
Address:
1445-885 WEST GEORGIA ST., VANCOUVER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing a proprietary pipeline of small molecule drug candidates targeting the CB1 and CB2 receptors. The company's main therapeutic programs address significant unmet medical needs, including preclinical candidates for Alzheimer’s disease (INM-901) and dry age-related macular degeneration (INM-089), as well as a completed Phase 2 clinical trial for epidermolysis bullosa. Additionally, through its subsidiary BayMedica, InMed manufactures and supplies high-purity, bioidentical rare cannabinoids (including CBC, d9-THCV, CBDV, and CBTC) as raw ingredients for the B2B health and wellness product market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all InMed Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for InMed Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for InMed Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NEXGEL, INC. Logo
Develops and manufactures advanced hydrogels for healthcare, OTC, and consumer applications.
United States of America NXGL
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NextCure, Inc. Logo
Clinical-stage biopharma developing novel immunomedicines for cancer and other diseases.
United States of America NXTC

Talk to a Data Expert

Have a question? We'll get back to you promptly.